Objective: To determine the extent to which the effects of intensive blood pressure (BP) lowering are modified by doses of alteplase in thrombolysis-eligible acute ischemic stroke (AIS) patients. Methods: Prespecified analyses of the Enhanced Control of Hypertension and Thrombolysis Stroke Study for patients enrolled in both arms: (i) low-dose (0.6 mg/kg body weight) or standard-dose (0.9 mg/kg) alteplase and (ii) intensive (target systolic BP [SBP] 130–140 mm Hg) or guideline-recommended (target SBP <180 mm Hg) BP management. The primary outcome was functional recovery, measured by a shift in scores on modified Rankin scale at 90 days. The safety outcome was any intracranial hemorrhage (ICH). Results: There were 925 participants (mean age 67 years, 39% female, 77% Asian) randomized to both arms: 242 randomly assigned to guideline/standard-dose (GS); 234 to guideline/low-dose (GL); 227 to intensive/standard-dose (IS); and 222 to intensive/low-dose (IL). Overall, average SBP levels within 24 h were lower in the low-dose compared to standard-dose alteplase group (146 and 144 vs. 151 and 150 mm Hg, for GS and GL vs. IS and IL, respectively, p < 0.0001). There was no heterogeneity of the effects of BP lowering (intensive vs. guideline) on functional recovery between standard-dose (OR 0.81, 95% CI 0.59–1.12) and low-dose alteplase (1.06, 0.77–1.47; p = 0.25 for interaction). Similar results were observed for ICH (p = 0.50 for interaction). Conclusions: In thrombolysis-treated patients with predominantly mild-to-moderate severity AIS, intensive BP lowering neither improve functional recovery, either with low- or standard-dose intravenous alteplase, nor beneficially interact with low-dose alteplase in reducing ICH. Trial Registration: The trial is registered with ClinicalTrials.gov (NCT01422616).

Keywords:
Acute ischemic stroke, Thrombolysis, Intracerebral hemorrhage, Blood pressure lowering, Hypertension
1.
Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, et al.; Neuroscience Institute. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study.
Stroke
. 2004 Feb;35(2):e27–9.
2.
Royal College of Physicians Intercollegiate Stroke Working Party.
National Clinical Guideline for Stroke
. 5th edition. Royal College of Physicians; 2016.
3.
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al.; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.
Stroke
. 2018 Mar;49(3):e46–110.
4.
Sharma VK, Ng KW, Venketasubramanian N, Saqqur M, Teoh HL, Kaul S, et al. Current status of intravenous thrombolysis for acute ischemic stroke in Asia.
Int J Stroke
. 2011 Dec;6(6):523–30.
5.
Liu MD, Ning WD, Wang RC, Chen W, Yang Y, Lin Y, et al. Low-Dose Versus Standard-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke in Asian Populations: A Meta-Analysis.
Medicine (Baltimore)
. 2015 Dec;94(52):e2412.
6.
Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al.; Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).
Stroke
. 2006 Jul;37(7):1810–5.
7.
Mori E, Minematsu K, Nakagawara J, Yamaguchi T, Sasaki M, Hirano T; Japan Alteplase Clinical Trial II Group. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II).
Stroke
. 2010 Mar;41(3):461–5.
8.
Anderson CS, Huang Y, Lindley RI, Chen X, Arima H, Chen G, et al.; ENCHANTED ­Investigators and Coordinators. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
Lancet
. 2019 Mar;393(10174):877–88.
9.
Anderson CS, Woodward M, Arima H, Chen X, Lindley RI, Wang X, et al. Statistical analysis plan for evaluating different intensities of blood pressure control in the ENhanced Control of Hypertension And Thrombolysis strokE stuDy.
Int J Stroke
. 2019 Jul;14(5):555–8.
10.
Huang Y, Sharma VK, Robinson T, Lindley RI, Chen X, Kim JS, et al.; ENCHANTED investigators. Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: an international multicenter 2 × 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment.
Int J Stroke
. 2015 Jul;10(5):778–88.
11.
Anderson CS, Robinson T, Lindley RI, Arima H, Lavados PM, Lee TH, et al.; ENCHANTED Investigators and Coordinators. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.
N Engl J Med
. 2016 Jun;374(24):2313–23.
12.
Anderson CS, Woodward M, Arima H, Chen X, Lindley RI, Wang X, et al.; ENCHANTED Investigators. Statistical analysis plan for evaluating low- vs. standard-dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED).
Int J Stroke
. 2015 Dec;10(8):1313–5.
13.
Wang X, Lee KJ, Moullaali TJ, Kim BJ, Li Q, Bae HJ, et al.; ENCHANTED Investigators. Who will benefit more from low-dose alteplase in acute ischemic stroke?
Int J Stroke
. DOI: 10.1177/1747493019858775.
14.
Durand CP. Does raising type 1 error rate improve power to detect interactions in linear regression models? A simulation study.
PLoS One
. 2013 Aug;8(8):e71079.
15.
Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial–Italy (MAST-I) Group.
Lancet
. 1995 Dec;346(8989):1509–14.
16.
Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al.; The European Cooperative Acute Stroke Study (ECASS). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke.
JAMA
. 1995 Oct;274(13):1017–25.
17.
Multicenter Acute Stroke Trial–Europe Study G, Hommel M, Cornu C, Boutitie F, Boissel JP. Thrombolytic therapy with streptokinase in acute ischemic stroke.
N Engl J Med
. 1996;335(3):145–50.
18.
Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group.
JAMA
. 1996 Sep;276(12):961–6.
19.
Brott T, Lu M, Kothari R, Fagan SC, Frankel M, Grotta JC, et al. Hypertension and its treatment in the NINDS rt-PA Stroke Trial.
Stroke
. 1998 Aug;29(8):1504–9.
20.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke.
N Engl J Med
. 1995 Dec;333(24):1581–7.
21.
Spence JD, Del Maestro RF. Hypertension in acute ischemic strokes. Treat.
Arch Neurol
. 1985 Oct;42(10):1000–2.
22.
Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice.
Nat Med
. 1998 Feb;4(2):228–31.
23.
Yamashita T, Kamiya T, Deguchi K, Inaba T, Zhang H, Shang J, et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain.
J Cereb Blood Flow Metab
. 2009 Apr;29(4):715–25.
24.
Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke.
Nat Med
. 2008 Jul;14(7):731–7.
25.
Kidwell CS, Latour L, Saver JL, Alger JR, Starkman S, Duckwiler G, et al.; UCLA Thrombolysis Investigators. Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke.
Cerebrovasc Dis
. 2008;25(4):338–43.
26.
Wildasin K. Neurotoxicity of tissue plasminogen activator.
Lancet Neurol
. 2004;3(12):P698.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.